Policy | March 19, 2025
Anupriya Patel inaugurates India Innovation Summit – Pioneering Solutions to End TB
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Subscribe To Our Newsletter & Stay Updated
